ArticleInternational journal of biological sciences2022
Identification and Validation of a Prognostic Model Based on Three MVI-Related Genes in Hepatocellular Carcinoma.
Article in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Using pre-operative radiomics to predict microvascular invasion of hepatocellular carcinoma based on Gd-EOB-DTPA enhanced MRI.BMC medical imaging · 2022Trial
- SLC16A3 links tumor metabolism to therapeutic opportunities in hepatocellular carcinoma.Translational cancer research · 2026Review
- Tissue factor promotes vascular invasion and metastasis in hepatocellular carcinoma via combined activation of β-catenin/STAT3 signaling.Molecular biomedicine · 2026Article
- Multi-omics characterization of cachexia-related genes reveals prognostic signatures and immune landscape in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Preoperative prediction of early recurrence and microvascular invasion in hepatocellular carcinoma using conventional ultrasound, elastography, and clinical nutritional indicators: a radiomics-based study.American journal of translational research · 2026Article
- Noninvasive prediction of microvascular invasion in hepatocellular carcinoma using a fusion model of 5-mm optimal peritumoral radiomics and imaging features based on multiphasic gadoxetic acid-enhanced MRI.Frontiers in oncology · 2026Article
- CT-based habitat imaging integrated with radiomics and clinicopathology for noninvasive prediction of microvascular invasion in hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Postoperative Adjuvant Transcatheter Arterial Chemoembolization (TACE) for Hepatocellular Carcinoma: Patient Selection and Clinical Predictors of Therapeutic Benefit.Journal of hepatocellular carcinoma · 2026Review
- A Novel Predictive Model Based on Glutathione Metabolism Genes RRM2 and G6PD in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Prediction models after hepatectomy for hepatocellular carcinoma-based ultrasonic radiomics: an observational study.European journal of medical research · 2025Observational
- Metabolic alterations driven by LDHA in CD8 + T cells promote immune evasion and therapy resistance in NSCLC.Scientific reports · 2025Article
- Machine learning-based detoxification enzymes-related genes prognosis model in breast cancer: immune landscape and clinical significance.Discover oncology · 2025Article
- Precision Nanotherapy for Spinal Cord Injury: Modulating SLC16A3 With Methylprednisolone-Loaded Nanoparticles.Neurospine · 2025Article
- Integrating gene demethylation and immune modulation: PD-1 nanovesicles as a dual-action therapy for NSCLC.Materials today. Bio · 2025Article
- An elevated percentage of CD4⁺CD25⁺CD127BMC gastroenterology · 2025Article
- Identifying key predictors of mortality and liver decompensation in hepatocellular carcinoma patients treated with transarterial radioembolization.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Identification of a novel FOXO3‑associated prognostic model in hepatocellular carcinoma.Oncology letters · 2025Article
- CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c-Myc Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The molecular characteristics of DNA damage and repair related to P53 mutation for predicting the recurrence and immunotherapy response in hepatocellular carcinoma.Scientific reports · 2025Article
- CCL26 as a prognostic biomarker in hepatocellular carcinoma: integrating bioinformatics analysis, clinical validation, and radiomics score.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MVI has significant clinical value for treatment selection and prognosis evaluation in hepatocellular carcinoma (HCC). We aimed to construct a model based on MVI-Related Genes (MVIRGs) for risk assessment and prognosis prediction in patients with HCC. This study utilized various statistical analysis methods for prognostic model construction and validation in the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) cohorts, respectively. In addition, immunohistochemistry and qRT-PCR were used to analyze and identify the value of the model in our cohort. After the analyses, 153 differentially expressed MVIRGs were identified, and three key genes were selected to construct a prognostic model. The high-risk group showed significantly lower overall survival (OS), and this trend was observed in all subgroups: different age groups, genders, stages, and grades. Risk score was a risk factor independent of age, gender, stage, and grade. Moreover, the ICGC cohort validated the prognostic value of the model corresponding to the TCGA. In our cohort, qRT-PCR and immunohistochemistry showed that all three genes had higher expression levels in HCC samples than in normal controls. High expression levels of genes and high-risk scores showed significantly lower recurrence-free survival (RFS) and OS, especially in MVI-positive HCC samples. Therefore, the prognostic model constructed by three MVIRGs can reliably predict the RFS and OS of patients with HCC and is valuable for guiding clinical treatment selection and prognostic assessment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.